Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37

Benzinga Newsdesk www.benzinga.com Negative 54.4%

Neg 54.4% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $40 to $37.